Swiss Lonza signs Agreement to divest Specialty Ingredients Business to Bain Capital and Cinven

Lonza Specialty Ingredients to be sold to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion

•             Divestment will allow Lonza to refocus its business as a pure-play partner to the healthcare industry

•             Successful track record of investment in industrials sector and portfolio companies confirms that Bain Capital and Cinven are the right home for the business

•             Smooth transition for employees and customers is a priority for both seller and buyers. The transaction is anticipated to close in H2 2021

Quote from Albert M. Baehny, Chairman, Lonza: “Today’s announcement is the result of a comprehensive and robust selection process.

Bain Capital and Cinven have shown they understand the value of the experience and expertise of our Specialty Ingredients employees. They presented the most compelling industrial strategy and vision for the business, they are also keen to prioritize R&D and innovation, as well as to invest in existing facilities to unlock the potential of the business.

The sale of the Specialty Ingredients business will allow Lonza to focus on its position as a leading partner to the healthcare industry, and the free cash flows resulting from the sale will allow us to accelerate our strategic priorities.

We look forward to continuing to collaborate with Bain Capital and Cinven to ensure a seamless transition for customers and employees.”

 Lonza has entered into a definitive agreement with Bain Capital and Cinven to acquire Lonza’s Specialty Ingredients business and operations for an enterprise value of CHF 4.2 billion.

 Both Bain Capital and Cinven have strong experience in the industrials sector and an established track record of successful investments in portfolio companies. The two private equity bidders showed strong and sustained interest since the beginning of the official sale process, thereby confirming that they are the best home for the business and the right transaction partner for Lonza.

Lonza’s Specialty Ingredients business operates across 17 manufacturing sites globally and has approximately 2800 permanent employees. The business is a leading provider of microbial control solutions for Professional Hygiene and Personal Care products. It also offers the custom development and manufacturing of specialty chemicals and composites to support the electronics, aerospace, food and agrochemical industries.

The transaction is expected to close in H2 2021, subject to customary closing conditions. The ownership transfer process is expected to be smooth. Bain Capital and Cinven have confirmed that high standards of service delivery and quality for customers will remain a priority following closing. 

BofA Securities and UBS are acting as joint financial advisors to Lonza.

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to  prevent  illness  and  enable  a  healthier  world  by  supporting  our  customers  to  deliver  new  and innovative medicines  that  help  treat  a  wide  range  of  diseases.  We  achieve  this  by  combining technological  insight  with  world-class  manufacturing,  scientific  expertise  and  process  excellence. These  enable  our  customers  to  commercialize  their  discoveries  and  innovations  in  the  healthcare sector.Founded in 1897 in the Swiss Alps, today Lonza operates across three continents.

With approximately 14000  full-time  employees,  we  are  built  from  high-performing  teams  and  of  individual  talent  who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 4.5 billion in 2020 with a CORE EBITDA of CHF 1.4 billion.

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to  prevent  illness  and  enable  a  healthier  world  by  supporting  our  customers  to  deliver  new  and innovative medicines  that  help  treat  a  wide  range  of  diseases.  We  achieve  this  by  combining technological  insight  with  world-class  manufacturing,  scientific  expertise  and  process  excellence. These  enable  our  customers  to  commercialize  their  discoveries  and  innovations  in  the  healthcare sector.Founded in 1897 in the Swiss Alps, today Lonza operates across three continents. With approximately 14,000  full-time  employees,  we  are  built  from  high-performing  teams  and  of  individual  talent  who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 4.5 billion in 2020 with a CORE EBITDA of CHF 1.4 billion.

www.lonza.com